Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre (KFSH&RC), Riyadh, Saudi Arabia.
Department of Medicine, King Faisal Specialist Hospital and Research Centre (KFSH&RC), Riyadh, Saudi Arabia.
Ann Clin Lab Sci. 2021 Jul;51(4):552-556.
The antiphospholipid syndrome (APS) is an autoimmune disease that is characterized by thrombosis and/or pregnancy failure and associated with the presence of all or at least one of three standard antibodies (anti-phospholipid (aPL) antibodies, including lupus anticoagulant (LA), anti-cardiolipin (aCL), and anti-β2-glycoprotein I (anti-β2GPI)). A growing body of evidence recommends adding additional aPL antibodies, such as anti-phosphatidylserine (aPS), anti-prothrombin (aPT), and anti-annexin A5 (aAA5), to conventional laboratory tests (revised Sapporo criteria), especially in seronegative APS cases.
We aimed to compare the diagnostic value, utility, and performance of these three additional antibodies along with the standard aPL antibodies in cases with confirmed and non-criteria APS (seronegative).
This was a prospective observational study on 59 patients who presented with clinical features of APS at the hematology, medical, rheumatology, and obstetric clinics. LA was detected by standard coagulation tests, while other aPL, IgG, and IgM antibodies (aCL, aβ2GPI, aPS, aPT, aAA5) were detected with enzyme-linked immunosorbent assay (ELISA).
Anti-PS antibody was more frequent compared to aPT and aAA5 in both confirmed cases (84.6%) and non-criteria (seronegative) (15.4%) APS. As a single test, the aPS antibody was significantly better (<0.05) than the aPT and aAA5 antibodies in the detection of APS cases. Seven non-criteria patients were confirmed using additional aPL antibodies. Among these patients, four, two, and one patient was confirmed with aPS, aPT, and aAA5 antibodies, respectively.
Our data support the findings of previously published studies and attribute the clinical significance of additional aPL antibodies, particularly aPS, in identifying non-criteria APS cases. In the future, along with conventional aPL antibodies, these additional antibodies should be included as standard laboratory tests in the revised Sapporo criteria.
抗磷脂综合征(APS)是一种自身免疫性疾病,其特征为血栓形成和/或妊娠失败,并与所有或至少一种三种标准抗体(抗磷脂(aPL)抗体,包括狼疮抗凝剂(LA)、抗心磷脂(aCL)和抗-β2-糖蛋白 I(抗-β2GPI))的存在有关。越来越多的证据建议在常规实验室检测(修订后的 Sapporo 标准)中添加其他抗磷脂抗体,如抗磷脂酰丝氨酸(aPS)、抗凝血酶原(aPT)和抗膜联蛋白 A5(aAA5),尤其是在血清阴性 APS 病例中。
我们旨在比较这三种额外抗体与标准 aPL 抗体在确诊和非标准 APS(血清阴性)病例中的诊断价值、效用和性能。
这是一项前瞻性观察性研究,纳入了 59 名在血液科、内科、风湿病科和产科门诊出现 APS 临床特征的患者。LA 通过标准凝血试验检测,而其他 aPL、IgG 和 IgM 抗体(aCL、aβ2GPI、aPS、aPT、aAA5)通过酶联免疫吸附试验(ELISA)检测。
在确诊病例(84.6%)和非标准(血清阴性)(15.4%)APS 中,抗 PS 抗体比 aPT 和 aAA5 更为常见。作为单项检测,aPS 抗体在检测 APS 病例方面明显优于 aPT 和 aAA5 抗体(<0.05)。通过添加其他 aPL 抗体,有 7 名非标准患者被确诊。在这些患者中,有 4 名、2 名和 1 名患者分别被 aPS、aPT 和 aAA5 抗体确诊。
我们的数据支持先前发表的研究结果,并认为额外的 aPL 抗体,特别是 aPS,在识别非标准 APS 病例方面具有临床意义。在未来,除了常规的 aPL 抗体之外,这些额外的抗体应该被纳入修订后的 Sapporo 标准中的常规实验室检测。